Gilead Sciences Files 8-K Report

TL;DR

Gilead filed an 8-K. Standard stuff, mostly financial exhibits.

AI Summary

On March 22, 2024, Gilead Sciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific new material events or financial figures beyond the standard reporting requirements were detailed in the provided excerpt.

Why It Matters

This filing serves as a standard disclosure for Gilead Sciences, Inc., providing updates on financial statements and other relevant events as required by the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not appear to contain any new material adverse information.

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — Registrant
• March 22, 2024 (date) — Date of Report
• 333 Lakeside Drive, Foster City, California 94404 (address) — Principal executive offices
• 650-574-3000 (phone_number) — Registrant's telephone number

FAQ

From the Filing

0001104659-24-037619.txt : 20240322 0001104659-24-037619.hdr.sgml : 20240322 20240322092118 ACCESSION NUMBER: 0001104659-24-037619 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240322 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 24773381 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 tm249475d1_8k.htm FORM 8-K false 0000882095 0000882095 2024-03-22 2024-03-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 22, 2024       GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter)       Delaware 0-19731 94-3047598 (State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)   333 Lakeside Drive , Foster City , California (Address of principal executive offices)   94404 (Zip Code)   ( 650 ) 574-3000 (Registrant’s telephone number, including area code)       Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 7.01. Regulation FD Disclosure.   On March 22, 2024, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), issued a press release announcing the completion of the acquisition of the CymaBay Therapeutics, Inc., a Delaware corporation (the “ Company ”), a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.   The information in Item 7.01 and Item 9.01 of this Form 8-K and Exhibit 99.1 shall